# Steroid-Responsive, Post-infectious New Daily Persistent Headache With Mild Cerebrospinal Fluid Pleocytosis: A Case Report

**Authors:** Shoji Kikui, Yoshiki Matsumoto, Daisuke Danno, Takao Takeshima

PMC · DOI: 10.7759/cureus.102843 · Cureus · 2026-02-02

## TL;DR

A man developed a persistent headache after a flu-like illness, and his symptoms improved with corticosteroid treatment, suggesting immune-related mechanisms may play a role.

## Contribution

This case report highlights a possible immune-related mechanism and corticosteroid responsiveness in post-infectious NDPH.

## Key findings

- A 42-year-old man with post-infectious NDPH showed mild cerebrospinal fluid pleocytosis.
- Intravenous and oral corticosteroids led to rapid and sustained headache resolution.
- Corticosteroid response may reflect reversible mechanisms of headache chronification.

## Abstract

New daily persistent headache (NDPH) is a primary headache disorder characterized by a clearly remembered onset, with the headache becoming daily and unremitting within 24 hours and persisting for more than 3 months. Although antecedent infections have been reported as potential triggering events, the pathophysiology of post-infectious presentations of NDPH remains incompletely understood, and effective treatment options are limited. We report the case of a 42-year-old man who developed a continuous daily headache following a flu-like illness and was diagnosed with NDPH according to the International Classification of Headache Disorders, 3rd edition. Cerebrospinal fluid examination revealed mild pleocytosis, while neurological examination and neuroimaging findings were unremarkable. Intravenous methylprednisolone therapy, followed by a short course of oral corticosteroids, resulted in rapid and sustained complete resolution of the headache. This case suggests that inflammatory or immune-related mechanisms may contribute to headache persistence in a subset of patients with NDPH triggered by antecedent infection. However, responsiveness to corticosteroid therapy does not necessarily indicate the presence of ongoing active inflammation and may instead reflect reversible modulation of mechanisms involved in headache chronification. Further studies are required to clarify the pathophysiology of post-infectious NDPH and to identify patients who may benefit from targeted therapeutic approaches.

## Linked entities

- **Chemicals:** methylprednisolone (PubChem CID 6741)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** sarcoidosis (MESH:D012507), ischemic (MESH:D002545), COVID-19 (MESH:D000086382), autoimmune, infectious, and post-COVID-19 conditions (MESH:D000094025), malignancy (MESH:D009369), venous sinus thrombosis (MESH:D012851), infection (MESH:D007239), CSF pleocytosis (MESH:D007964), Chronic meningitis (MESH:D008580), hepatitis B (MESH:D006509), hepatitis C (MESH:D019698), arterial abnormalities (MESH:D000071079), Headache Disorders (MESH:D020773), syphilis (MESH:D013587), chronic tension-type headache (MESH:D018781), Headache (MESH:D006261), inflammation (MESH:D007249), photophobia (MESH:D020795), venous outflow obstruction (MESH:D006502), flu (MESH:D007251), CSF abnormalities (MESH:D002559), sore throat (MESH:D010612), chronic migraine (MESH:D008881), fever (MESH:D005334), Viral meningitis (MESH:D008587), human immunodeficiency virus (MESH:D015658), neurological deficits (MESH:D009461), fungal infection (MESH:D009181), vomiting (MESH:D014839), autoimmune, and infectious disorders (MESH:D003141), autoimmune disease (MESH:D001327), phonophobia (MESH:D012001), nausea (MESH:D009325), tuberculosis (MESH:D014376)
- **Chemicals:** prednisolone (MESH:D011239), tizanidine (MESH:C023754), etizolam (MESH:C044610), glucose (MESH:D005947), methylprednisolone (MESH:D008775), diclofenac (MESH:D004008), Steroid (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human alphaherpesvirus 3 (Varicella-zoster virus, no rank) [taxon 10335]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12959850/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12959850/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12959850/full.md

---
Source: https://tomesphere.com/paper/PMC12959850